During the past decade, Moscow City Oncology Hospital #62 conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 26 clinical trials were completed, i.e. on average, 60.5% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 17 clinical trials were completed. i.e. 113.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Moscow City Oncology Hospital #62" #1 sponsor was "Hoffmann-La Roche" with 30 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "Biocad" with 5 trials sponsored, "Eisai Inc." with 2 trials sponsored and "Alaunos Therapeutics" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Moscow City Oncology Hospital #62" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "GOG Foundation" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Moscow City Oncology Hospital #62" are "Breast Cancer" (5 trials), "Non-Small Cell Lung Cancer" (5 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Early Breast Cancer" (3 trials) and "Melanoma" (3 trials). Many other conditions were trialed in "Moscow City Oncology Hospital #62" in a lesser frequency.

Most popular intervention types in "Moscow City Oncology Hospital #62" are "Drug" (55 trials), "Biological" (5 trials), "Other" (4 trials), "Procedure" (4 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Carboplatin" (15 trials), "Atezolizumab" (9 trials), "Paclitaxel" (9 trials) and "Pemetrexed" (8 trials). Other intervention names were less common.

The vast majority of trials in "Moscow City Oncology Hospital #62" are 44 trials for "All" genders, 8 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Moscow City Oncology Hospital #62". undefined are not yet recruiting, 8 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Moscow City Oncology Hospital #62, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Moscow City Oncology Hospital #62, 3 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".